THAR: Tharimmune Inc Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Tharimmune Corp (THAR)

Successes in the development of the TH104 antibody and patent potential are driving the creation of unique biologics, which is reflected in the historical P/S of Tharimmune, Inc. (THAR) on GURU.Markets through valuation dynamics, where the value indicates the current magnitude. The picture is completed by strict control of pharmaceutical logistics, guaranteeing patient safety and the precision of clinical trials in oncology.

Price-to-Revenue Ratio: tharimmune.com (THAR) for 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Tharimmune Corp (THAR)

- stock quotes and analyst forecast:
Price tharimmune.com|THAR - Analyst Consensus Forecast
- market capitalization information:
Market Value Tharimmune Corp|THAR - Enterprise Value
- book capitalization indicators:
Book Value per Share Tharimmune|THAR - Company Book Value|Market Value to Book Value tharimmune.com|THAR - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Tharimmune, Inc.|THAR - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Tharimmune Corporation|THAR - Company Debts|Debt to Book Value Tharimmune Corp|THAR - Company Long-Term Liabilities|Company Short-Term Debts Tharimmune|Immediate Liquidity Ratio tharimmune.com
- company profitability and valuation multiples indicators:
THAR - Net Profit|Expected Net Profit Tharimmune, Inc.|THAR - Price to Earnings Ratio|Future Price to Earnings Multiple Tharimmune Inc|THAR - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Tharimmune Corp|THAR - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Tharimmune|THAR - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months tharimmune.com|THAR - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Tharimmune, Inc.
- total revenue and sales volume data:
THAR - Company Sales|Company Projected Revenue Volume tharimmune.com|THAR - P/S Multiple|Forward Price to Sales Tharimmune Corp
Fundamental company analysis:THAR (tharimmune.com)
Core merchandise of Tharimmune, Inc.

The P/S ratio reflects the market value of one dollar of revenue, correlating market capitalization with the issuer's actual trading turnover. For Tharimmune, Inc. (THAR), which develops unique antibodies for dermatological and hepatic pathologies, this coefficient measures market expectations regarding the future commercialization of its therapies. By analyzing the business valuation via P/S, an investor determines the extent of the premium paid for innovation potential. This metric allows for an objective comparison of the asset's value against its current operational efficiency.

Who Tharimmune, Inc. competes with

Market Cap to Sales Volume ONC|P/S Multiple HALO (Halozyme)|Market Capitalization-to-Revenue Ratio RVMD|Ascentage - P/S Multiple|CGON - P/S Multiple|UroGen Pharma Ltd. (URGN) - Price-to-Revenue Ratio|bicara.com - Market Capitalization-to-Revenue Ratio|PSNL (Personalis) - P/S Multiple|Erasca Inc (ERAS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Delcath (DCTH)|Market Cap to Revenue Y-mAbs Corp YMAB|Price-to-Revenue Ratio Aura Biosciences, Inc. AURA|CADL - Market Cap to Revenue|ARAY: Market Cap to Revenue|SLS - P/S Multiple|Actuate Therapeutics, Inc (ACTU) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CTOR|HURA (TuHURA Biosciences Inc.) - P/S Multiple|Price to Sales protaratx.com TARA|Market Cap to Revenue FATE (Fate Therapeutics)|WHWK (aadibio.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple TCRX (TScan Therapeutics, Inc.)|Price-to-Revenue Coefficient Champions Oncology Inc (CSBR)|XBIT - Price-to-Revenue Ratio|CVM (CEL-SCI Corporation) - Market Cap to Revenue Ratio|OSTX: P/S Multiple|Market Cap to Revenue radiopharmtheranostics.com|Market Cap to Revenue ARTV|Adlai Nortye Limited (ANL) - Price-to-Revenue Coefficient|Market Cap to Revenue VERU (Veru Inc.)|Market Cap to Sales Volume TPST|P/S Multiple XLO (Xilio Therapeutics)|Market Capitalization-to-Revenue Ratio RENB|Mural Bio - P/S Multiple|KAPA - P/S Multiple|onkuretherapeutics.com (OKUR) - Price-to-Revenue Ratio|CytoMed Therapeutics Limited - Market Capitalization-to-Revenue Ratio|CRIS (Curis Inc.) - P/S Multiple|Market Cap to Revenue Apollomics Corp (APLM)|P/S Multiple ADVB|P/S Multiple Genprex Inc (GNPX)|Price-to-Revenue Ratio Calidi Biotherapeutics, Inc. CLDI|SBFM: Market Cap to Revenue Ratio|Xenetic Bio - P/S Multiple|Salarius Pharmaceuticals Inc (SLRX) - Market Cap to Revenue|PPBT: P/S Multiple|Price to Sales American Oncology Network, Inc. (AONC)|Price-to-Revenue Ratio BeiGene, Ltd.|CKPT: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue ELEV (Elevation Oncology)|ICAD (icadmed.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple IKNA (Ikena Oncology)|NTBL - Market Cap to Revenue|VIRX: Market Cap to Revenue|MOR - P/S Multiple|NAYA Biosciences Inc. (NAYA) - Price-to-Revenue Ratio|Ascentage Pharma Group International - Market Capitalization-to-Revenue Ratio